Series of Preclinical Studies Supports the Army’s Pan-Coronavirus Vaccine Development Strategy
NPC-131072 writes:
Series of preclinical studies supports the Army's pan-coronavirus vaccine development strategy:
A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research (WRAIR) not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.
Scientists in WRAIR's Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking "pan-SARS" strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.
[...] SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN's potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN's immune profile to that of other COVID-19 vaccines already authorized for emergency use.
Journal Reference:
M. Gordon Joyce, Hannah A. D. King, Ines Elakhal-Naouar, et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates, Science Translational Medicine(DOI: https://www.science.org/doi/10.1126/scitranslmed.abi5735
Read more of this story at SoylentNews.